Probiota Asia 2019: Medlab to assess mood disorders and the power of probiotics

Probiota-Asia-2019-Medlab-to-assess-mood-disorders-and-the-power-of-probiotics.jpg
The event takes place in Singapore in October.

Probiotic brand Medlab has been added to the agenda for the forthcoming Probiota Asia summit in Singapore, where its Director of Medical Research will assess the benefits of probiotics for mood disorders.

Prof Luis Vitetta will deliver his talk, titled ‘Mood Disorders and the Brain–Intestinal Mucosa–Appendix–Microbiome–Brain Loop’ at the event which takes place at the Hilton hotel from October 22-24.

He said: “The brain and the gut are connected from early foetal life and the mother's exposure to microbial molecules is thought to exert in utero developmental effects on the foetus. These effects could underpin the groundwork for subsequent pathophysiological mechanisms for achieving immunological tolerance and metabolic equilibrium post birth, events that continue through to 3-4 years of age.”

His presentation will focus on how the microbiome promotes cues that instruct the neonate's mucosal tissues and skin in the language of molecular and cellular biology.

It will examine how post-birth mucosal lymphoid tissue formation and maturation (most probably including the vermiform appendix) is microbiota-encouraged and co-establishes the intestinal microbiome with a developing immune system.

“Furthermore, Intestinal mucosal tissue maturation loops the brain-gut-brain and is postulated to influence mood dispositions via adverse shifts in the intestinal microbiome phyla,” he added.

Key takeaways will include:

  • An understanding of the overarching role of the intestinal microbiome in maintaining homeostasis of end organ and how it may promote cognitive health.
  • How commensal and pathobiont bacteria teach the human host the fundamental language of molecular biology that is vital for appropriate immune functions and adaptations.
  • Discuss the beneficial effect that the administration of probiotic and prebiotic formulations may have on mood disorders.

From 2007 to 2013 Luis was the Director and Professor of the Centre for Integrative Clinical and Molecular Medicine at the University of Queensland, Faculty of Medicine, based at the Princess Alexandra Hospital in Brisbane.

In 2013 he joined Medlab Clinical, where he now conducts research on the intestinal microbiome in the areas of mood disorders, metabolic diseases, pain and skeletal muscle health.  Consequently, Luis has research interests in the microbiome / nutrition / probiotics / prebiotics and mucosal and cellular immunity as well as research on cannabis medicines.

Other confirmed speakers include:

  • Dr Sam Costello, Consultant Gastroenterologist and Head of IBD Research at The Queen Elizabeth Hospital in Adelaide
  • Dr Gregory Lambert, CEO and VP of Research & Development, TargEDys
  • Dr Natarajan Ranganathan, Founder and Managing Director of Kibow Biotech Inc
  • Thomas Hayes, Analyst, Emerging Ecosystems in Agrifood & Health, Lux Research
  • Dr Vineet Sharma, Associate Professor, Metagenomics and Systems Biology Laboratory, Department of Biological Sciences, Indian Institute of Science Education and Research Bhopal, India
  • Lillian Fan, Antion (Beijing) Information Consulting Co., Ltd
  • Dr Bejit Ideas, Laboratory Director, Japanese Society of Anti-Aging Nutrition
  • Rieko Shofu, Founder, Sensing Asia
  • Ewa Hudson, Director of Insights, Lumina Intelligence, William Reed Business Media
  • Dr Anders Henriksson, Research Fellow, Food Science and Technology
  • Programme, Department of Chemistry, National University of Singapore
  • Dr Shanthi Parkar, Science Team Leader, Microbiome & Metabolism, New Zealand of Plant & Food Research.

To register, visit: https://www.probiotaasia.com/register/

For sponsorship and commercial partnership queries, please contact Sue Ann Peh or Tim Evans.